Sagimet Biosciences Q3 net loss narrows as costs drop

Sagimet Biosciences

13/11/2025 12:41

Overview

Sagimet reports Q3 net loss of $12.9 mln

R&D expenses for Q3 2025 decreased to $9.7 mln from $12.7 mln in Q3 2024

Cash and equivalents stand at $125.5 mln as of September 30, 2025

Outlook

Sagimet anticipates Phase 1 trial data readout for denifanstat and resmetirom in 1H 2026

Company plans Phase 2 trial for denifanstat and resmetirom pending regulatory consultation

Sagimet expects Phase 2 acne trial in 2026 following TVB-3567 Phase 1 trial

Result Drivers

CLINICAL TRIALS - Initiated Phase 1 PK trial for denifanstat and resmetirom combination, targeting MASH with F4 fibrosis

ACNE DEVELOPMENT - Ongoing Phase 1 trial of TVB-3567 for acne indication

COSTS DROP - R&R and G&A expenses decline, helping overall results

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$12.91 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Sagimet Biosciences Inc is $28.00, about 68.5% above its November 12 closing price of $8.82

Press Release: ID:nGNX3XMnkp

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)